No abstract

Hematopoietic stem cell and solid organ transplant recipients diagnosed with biopsy-confirmed posttransplant lymphoproliferative disorder (PTLD) at our institution from 1989 to 2010 were identified. Patient-, transplant- and disease-related characteristics, prognostic factors and outcome were collected and analyzed. One hundred and forty biopsy-proven cases of PTLD were included. Overall incidence in the transplant population was 2.12%, with heart transplant recipients carrying the highest risk. Most PTLDs were monomorphic (82%), with diffuse large B-cell lymphoma being the most frequent subtype. The majority of cases (70.7%) occurred > 1 year posttransplant, and 66% were Epstein-Barr virus positive. Following initial therapy the overall response rate was 68.5%. Three-year relapse-free and overall survivals were 59% and 49%, respectively. At last follow-up, 44% of the patients were alive. Multivariable analysis identified several classical lymphoma-specific poor prognostic factors for the different outcome measures. The value of the International Prognostic Index was confirmed in our analysis.

No abstract

ABSTRACTconventional CT scan less appropriate for adequate staging and less suitable for image-guided biopsy.Recently, 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) combined with CT has emerged as the most sensitive and specific imaging modality for diagnosis and staging of both Hodgkin's and different subtypes of aggressive non-Hodgkin's lymphoma. 4 The role of FDG-PET scan in PTLD, however, has not yet been established.Our aim was to evaluate the accuracy and clinical performance of FDG-PET scan in the diagnosis of PTLD in a large cohort of transplant recipients.

Staging FDG PET/CT is superior to CT and may be used in the future for identification of a subset of MCL patients with a better outcome than otherwise expected.